ADZA Adeza Biomedical (MM)

Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson, president and chief executive officer, will make an investment community presentation at the UBS Global Life Sciences Conference on Wednesday, September 27 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference is being held at the Grand Hyatt New York. A live audio presentation will be available via the Internet by visiting the Investor Relations section of the company's Web site at www.adeza.com. An archive of the presentation will be available on the Web site for 14 days. For more information about this conference visit www.ibb.ubs.com. About Adeza Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm(TM), The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. In May 2006, Adeza announced the submission of its New Drug Application (NDA) to the FDA for Gestiva(TM), a long-acting form of a naturally occurring progesterone to prevent preterm birth in women with a history of preterm delivery. On August 29, 2006 the Reproductive Health Drugs Advisory Committee to the FDA recommended by majority vote that the data presented by Adeza in its NDA support efficacy in preventing preterm birth prior to 35 weeks and that overall safety data was adequate and sufficiently reassuring to support marketing approval of Gestiva for women with a history of preterm delivery. The Advisory Committee also recommended the collection of post-marketing clinical data. Although Advisory Committee recommendations are not binding, typically FDA final determinations are consistent with their recommendations. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, the FDA has a goal to complete its review or otherwise respond to the Gestiva NDA by October 20, 2006. More information is available at www.adeza.com. Adeza cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including for example, statements related to Gestiva's regulatory status and medical potential. The inclusion of forward-looking statements should not be regarded as a representation by Adeza that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Adeza's business including, without limitation, risks related to the anticipated regulatory or commercial path for its product candidates. Further information about these and other risks is included Adeza's Annual Report on Form 10-K and other periodic and current reports filed by Adeza with the Securities Exchange Commission, which are available from the SEC's Web site (www.sec.gov), and also available on the Investor Relations section of Adeza's Web site. All forward-looking statements are qualified in their entirety by this cautionary statement and Adeza undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.